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Summary An antibody, 21N, raised against a synthetic peptide from the predicted sequence of the c-erbB-2
protein has been used immunocytochemically in a retrospective study of formalin fixed paraffin embedded
breast biopsies. Fourteen out of 103 infiltrating ductal carcinomas exhibited positive membrane staining.
Fifty-four of these tumours had lymph node involvement of which nine contained stained cells. These were all
cases where the primary tumour was positive. In this series there was no correlation between c-erbB-2
overexpression and lymph node status. In five of the positive cases studied there was an associated in situ
component which was also positively stained. Ten out of 24 pure intraduct carcinomas showed membrane
staining, but none of the 149 benign conditions studied, which included 22 radial scars and 13 cases of
atypical ductal proliferation, demonstrated the pattern of staining associated with overexpression. It is
concluded that the c-erbB-2 protein is overexpressed in a minority (- 14%) of infiltrating ductal carcinomas
and only in cells that are cytologically malignant. Overexpression of c-erbB-2 is considered in relation to
pathogenesis.
The c-erbB-2 gene is a normal cellular gene which is present
on chromosome 17 (Fukushige et al., 1986) and encodes a
protein which has close sequence homology with the epi-
dermal growth factor receptor (Coussens et al., 1985;
Bargmann et al., 1986a). This gene was originally identified in
ethyl nitrosourea induced rat neuroblastoma cell lines as an
activated oncogene called neu (Padhy et al., 1982; Bargmann
et al., 1986b). Neu was shown to encode a 185,000 molecular
weight protein, which from its structure (Coussens et al.,
1985; Bargmann et al., 1986a,b) and localisation to the
membrane (Drebin et al., 1984) suggests that it may be a
receptor for an as yet unidentified growth factor. In rat cell
lines the oncogenic-neu gene differs from the cellular-neu
gene by a single base change (glutamic acid to valine) in the
putative transmembrane region (Bargmann et al., 1986b).
Clinical interest in the gene in breast cancer was initiated
by a report from Slamon's group which indicated that
amplification of this gene may be related to poor prognosis,
with the claim that amplification alone had greater prognos-
tic value than hormonal-receptor status in lymph node-
positive patients (Slamon et al., 1987). Work on cell lines
had previously shown that in human breast carcinoma the
c-erbB-2 gene could be overexpressed by a number of
mechanisms, one of which was amplification (Kraus et al.,
1987). More recently of perhaps more biological significance
was the observation by Di Fiore et al. (1987) that c-erbB-2
needed to be overexpressed in NIH/3T3 cells (5-10 times) to
be transforming. The fact that the cellular gene could be
transforming without the point mutation supported the view
that overexpression of this gene in breast carcinomas could
have significance for the pathogenesis of this disease. Sub-
sequent to the Slamon paper other groups, including our
own, have confirmed the high incidence of c-erbB-2 amplifi-
cation in breast cancer (van de Vijver et al., 1987; Venter et
al., 1987; Varley et al., 1987; Zhou et al., 1987) and two of
these have also indicated a correlation between amplification
and poor prognosis (Varley et al., 1987) and between gene
amplification and lymph node metastases (Zhou et al., 1987).
On the basis of the c-erbB-2 protein sequence, Gullick's
group produced two polyclonal antibodies to c-terminal
peptides (Gullick et al., 1987). Using one of the antibodies it
was demonstrated that amplification, which was present in
12 out of 36 tumours, correlated with overexpression of the
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c-erbB-2 protein, measured immunocytochemically and by
Western blotting (Venter et al., 1987). In a subsequent
publication using the same series of tumours we have shown
that strong membrane staining using one of the antibodies,
21N, correlated with gene amplification (Gusterson et al.,
1987). Measurement of EGF receptor and oestrogen receptor
status in this same series showed no significant correlation
with c-erbB-2 overexpression (Gusterson et al., 1987). This
preliminary study, which was carried out on formalin fixed
paraffin embedded material, indicated the utility of antibody
21N for retrospective analyses of tumours and benign breast
diseases. The present paper describes an extensive immuno-
cytochemical study of infiltrating ductal carcinomas, lymph
node metastases, intraduct carcinomas and a range of benign
breast disease, including 22 radial scars and 13 cases of
atypical ductal proliferation.
Materials and methods
Tissues used
This study was carried out on 103 cases of infiltrating ductal
carcinoma, selected into two groups on the basis of the
lymph node status of the patients at the time of primary
breast surgery and division of the patients into those that
had relapsed within one year and those that were disease free
after five years.
In addition 24 cases of intraduct carcinoma were examined
and 150 examples of benign breast disease taken from
material obtained at the Guildford Breast Screening Pro-
gramme. Access to this material gave us the opportunity of
examining 22 stellate scars and 13 cases of atypical ductal
proliferation. All of the material was formalin fixed and
paraffin embedded.
Antibody and immunocytochemistry
Antibody 21N, raised to a synthetic peptide at the c-terminal
end of the c-erbB-2 protein, has been shown to precipitate a
190,000 mol. wt glycoprotein from human cells (Gullick et
al., 1987). In a previous study it had been demonstrated that
using antibody 21N membrane staining correlated with
c-erbB-2 gene amplification (Gusterson et al., 1987). It has
been shown by Dr N. Hynes that membrane staining with
this antibody also correlates with increased c-erbB-2 protein
expression (personal communication). On the basis of these
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data all of our analyses have been carried out using the
antibody titrated against a tumour sample with a 12-fold
gene copy number and strong membrane staining. In this
study we are therefore aiming to identify the stages in
tumour development at which overexpression occurs, the
clinical significance of overexpression, and whether over-
expression correlates with any identifiable morphological
change.
Immunocytochemical staining was carried out using the
indirect immunoperoxidase technique. Dewaxed sections
were washed in PBS, and endogenous peroxidase blocked
with 0.1% phenylhydrosine hydrochloride in PBS for 5min
at room temperature. After washing in PBS, sections were
exposed to the first antibody diluted to 3.3jugml-1 in PBS
for 1.5 h at room temperature. This concentration was based
on a previous titration of the antibody against a tumour
with a known 12-fold amplification of the c-erbB-2 gene
(Gusterson et al., 1987).
After washing in PBS, sections were incubated with lOOpl
sheep anti-rabbit peroxidase conjugate (Dako, High
Wycombe, Bucks), at a dilution of I in 100, for I h. The
colour was developed using diaminobenzidine (DAB) [10mg
DAB in 100ml Tris buffer (pH 7.2) 0.1 M, 100ml M.O, 66kl
H202] for 5min. Sections were dehydrated, cleared and
mounted in histomount (National Diagnostics). Control
sections included omission of the first antibody and prior
absorption of the antibody with peptide (1 mgml 1) at room
temperature for 2min.
Results
Morphological analyses
Of the 103 infiltrating carcinomas in this study there were 93
ductal carcinomas, 9 lobular carcinomas and 1 medullary.
Strong membrane staining was seen in 14 of the ductal
carcinomas together with a weak cytoplasmic blush (Figure
la,b). In two of the lobular carcinomas there was cytoplas-
mic staining which was both diffuse and granular in type.
The single medullary carcinoma was negative. Fifty-seven
cases of infiltrating carcinoma had lymph node metastases.
The primary tumours were stained in parallel with represen-
tative sections of the lymph nodes. Nine primary tumours of
the original 14 positive cases had lymph node involvement
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Figure 1 (a) shows strong membrane staining of an infiltrating ductal carcinoma. The apical membranes of the cells adjacent to
the lumena are negative. (b) is a parallel section in which the antibody has been prior absorbed with the peptide - this extinguishes
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and an identical pattern of staining was seen in the meta-
static deposits. There was no-evidence of positive staining in
any of the metastases where the primary was negative (Table
I). This led us to conclude that overexpression of this protein
was not related to the metastatic process. Of the 14 positive
cases, five had an in situ component and in all instances the
staining pattern was identical with the infiltrating compo-
nent, suggesting that the protein was overexpressed in a
small percentage of tumours as a relatively early event in
tumorigenesis. In all of the cases where there was strong
membrane positivity the tumours were relatively homo-
geneously positive.
On the basis of the findings in these five intraduct
carcinomas it was decided to extend the study to benign
lesions and intraduct carcinoma biopsies from a breast
screening centre where large numbers of small tumours and
atypical lesions were available. The aim was to identify the
earliest morphological changes associated with membrane
positivity.
Ten of the 24 intraduct carcinomas from the screening
centre were positively stained on the membrane. Where a
single row of tumour cells lined the ducts the staining was
concentrated on the lateral and basal membranes with
absence of staining on the luminal surface (Figure 2). Where
Table I 21N staining in primary tumours and
lymph node metastases.
Lymph node
+ve -ve
Primary tumour +ve 9 0
-ve 0 45
Figure 2 Sections show an intraduct carcinoma. There is
strong staining of the pleomorphic tumour cells. Both the normal
ductal cells and the surrounding stromal cells are negative. Note
the absence of staining of the luminal membrane of the tumour
cells ( x 250).
there was multilayering tumour cells were positive on their
adjacent membranes. There was a clear delineation between
the positive tumour cells and the adjacent normal cells. In no
instances were cells strongly positive on the membranes that
were not cytologically malignant. In some micropapillary
intraduct carcinomas there was a loss of staining on the cells
towards the lumen. This was associated with central necrosis
and was interpreted as due to cellular degeneration.
The results of the benign lesions examined is shown in
Table II. Only one case of apocrine metaplasia showed
membrane staining and this was weak and on three cells in
one cyst wall. The staining was interpreted as due to an
artefact produced by fixation. The moderate cytoplasmic
staining, which was a consistent finding in apocrine meta-
plasia in all of the material, when concentrated in a sub-
membrane location as a result of fixation would give the
impression of membrane staining. In one case of atypical
epitheliosis there was marked cytoplasmic staining of cyto-
logically abnormal cells which were present in a lobule, the
significance of which is difficult to assess. There was no
evidence of membrane positivity in any of the other cases
examined including 22 stellate scars.
Clinical correlation
Data were available on 102 of the carcinoma cases for
analysis using Chi-squared test with Yates correction. There
was no correlation between the 21N staining and nodal
status (X2 =0.2) or disease free interval (x2 =0.4) (Table III).
When the data were analysed comparing 21N positive and
21N negative patients in relation to disease free survival and
overall survival (Figures 3 and 4) overexpression of c-erbB-2
had no prognostic significance (x2 = 1.45 and 3.37
respectively).
Discussion
This communication describes the distribution of the
c-erbB-2 protein in the human breast. From these data we
have concluded that overexpression of the c-erbB-2 protein
can be visualized immunocytochemically as membrane stain-
ing in approximately 14% of breast carcinomas. In this small
series there is no significant correlation of staining with
tumour progression or lymph node involvement. There was
also no relationship to either tumour grade or stage.
Although not statistically significant, both the overall survi-
val data and the disease free survival show a trend indicating
that 21N positivity may be a poor prognostic factor. A much
larger series with a longer follow-up is required to confirm
this observation. The morphological studies would suggest
that overexpression is an early event in tumorigenesis but in
the classical two-stage carcinogenesis model would be con-
sidered as post initiation.
In this study overexpression of the c-erbB-2 protein has an
apparently higher incidence (40%) in pure intraduct carcino-
Table II 21N staining in intraduct carcinoma and benign breast disease.
Weak
Positive cytoplasmic Negative Total
Ductal*carcinoma in situ 10 (M) 8 6 24
Epitheliosis 0 2 4 6
Atypical epitheliosis 1 (C) 3 9 13
Radial scars 1 (C) 1 20 22
Papillomata 0 0 6 6
Adenosis 0 2 4 6
Blunt duct adenosis 0 0 14 14
Sclerosing adenosis 0 0 4 4
Apocrine metaplasia 1 (C-M) 24 7 32
Cysts (including duct ectasia and involution) 0 0 22 22
Fibroadenomatoid hyperplasia 0 1 2 3
Fibroadenoma 0 5 16 21
M =Membrane; C =Cytoplasmic.456 B.A. GUSTERSON et al.
Table III Infiltrating ductal carcinoma.
Disease free interval
< I year >5 years
21N staining +ve 6 8
-ve 27 62
XF 100
a) 80 _l,21N negative
7Co_A - -- -- - - - --
50 21N positive
o 40
. 30
co 20
-0
0 88 64 61 61 61 51 42 26 15 4 2 1
0 lo 14 8 8 8 8 6 5 3 1 0 0 0
o 1 2 3 4 5 6 7 8 9 lo 11 12
Time since histology (years)
Figure 3 Disease-free survival.
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Figure 4 Survival from breast cancer.
mas than infiltrating tumours. The high incidence in these in
situ lesions is of interest as these cases were all identified at
screening. The question has been previously raised whether
these radiologically identified lesions would have presented
later as clinical cancers or perhaps form a sub-group of
tumours which would remain in situ or even possibly regress.
In fact Millis and Thyme (1975) have raised the interesting
possibility that these cases may represent a tumour that has
a long dormancy with little clinical importance to the
patient. It should be noted that with only 14% of cases
positive a relatively small number of tumours were available
for analysis and a much larger series would be required to
provide a definitive answer.
The weak cytoplasmic staining seen in some cases was
seen in all sections when the concentration of the antibody
was increased (Gusterson, unpublished). There was not,
however, an increase in the number of tumours with mem-
brane staining. Under such conditions all of the cells in the
section were stained including inflammatory cells, fibroblasts
and smooth muscle in vessel walls. The strong membrane
staining observed in some of the tumours, which correlates
with overexpression, is also seen in cultured breast car-
cinoma cells where BT474 cells which have a 125-fold in-
crease in mRNA for c-erbB-2 compared with MCF7 cells
(Kraus et al., 1987) show strong membrane staining while
MCF7 cells are only weakly cytoplasmically positive
(Gusterson, unpublished).
A number of facts indicate that the c-erbB-2 protein may
have an important role in the pathogenesis of human breast
cancer. Firstly the structure of the protein and its membrane
localisation suggest that it may be a growth factor receptor
(Coussens et al., 1985; Bargmann et al., 1986a). Secondly the
c-erbB-2 gene is consistently overexpressed and/or amplified
in a significant proportion of infiltrating breast carcinomas
in a number of series. The recent demonstration by Di Fiore
et al. (1987) that the transforming ability of this gene is
related to the level of expression of the protein further
supports the view that the demonstration of an over-
expressed protein in a proportion of breast carcinomas may
be related to a specific association with the mechanism of
transformation rather than an incidental observation.
Further support for a growth regulatory role of c-erbB-2 is
the observation that a monoclonal antibody reactive with the
extracellular domain exerted an anti-tumour effect on neu-
transformed NIH3T3 cells (Drebin et al., 1986). In order to
investigate the function of this protein further it will be
necessary to produce antibodies that recognise the human
external domain. Such antibodies may act as agonists or
produce blocking of the putative binding site. They may also
provide reagents for radio-localisation studies in a small but
easily definable group of breast carcinomas. The absence- of
membrane staining in normal tissues indicates that this latter
approach may be worth pursuing.
Although it is suggested that the c-erbB-2 protein may be
a receptor for an unknown growth factor it is worth
considering other possibilities. The sevenless gene in Droso-
phila encodes a putative transmembrane protein that has a
similar structure and sequence homology to hormone recep-
tors including the epidermal growth factor receptor (EGFR)
(Hafen et al., 1987). The sevenless protein is required for the
formation of the R7 photoreceptor in each ommatidium of
the compound eye. It has been suggested that the protein
controls this differentiation step by providing positional
information, either by cell-cell interaction or through locally
diffusable factors (Tomlinson et al., 1987). By analogy it
could be speculated that the EGFR, which is known to be
expressed on both proliferating and terminally differentiated
cells (Gusterson et al., 1984) and the c-erbB-2 protein with
its overexpression on adjacent cell membranes may also be
involved in cell-cell interactions. A study of c-erbB-2 expres-
sion in the human embryo and in particular in the develop-
ing breast may provide further clues to the function of this
molecule.
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